ArticleScience advances2026
Machine learning-powered single-molecule cancer diagnosis using DNA origami tags.
Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Single-molecule detection (SMD) holds considerable promise in biomedical research. Although atomic force microscopy (AFM) provides an important technique with nanoscale resolution for SMD, its broader application is limited by labeling challenges and slow data processing. Here, we present a machine learning (ML)-powered strategy combining AFM and DNA nanotags for SMD and cancer diagnosis. Nickases are applied to create specific single-strand breaks in target DNA, allowing insertion of exogenous DNA to attach shape-distinct nanotags for AFM imaging. A YOLOv5l algorithm is adopted to automatically recognize target objects in AFM images, which can classify 370 structures in 1.21 seconds with 98% accuracy. The proof of concept of this strategy is confirmed by identifying nickase-edited sites on both linear and circular DNA. Its practical applicability is demonstrated by detecting KRAS Gly12Arg (G12R) and p53 Arg175His (R175H) mutations in samples from patients with pancreatic and colorectal cancer, with accuracy rivaling Sanger sequencing and quantitative polymerase chain reaction, opening avenues for SMD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.